247 related articles for article (PubMed ID: 25723455)
1. New approaches for the selection and evaluation of anti-prion organic compounds.
Cordeiro Y; Ferreira NC
Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455
[TBL] [Abstract][Full Text] [Related]
2. Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.
Ferreira NC; Marques IA; Conceição WA; Macedo B; Machado CS; Mascarello A; Chiaradia-Delatorre LD; Yunes RA; Nunes RJ; Hughson AG; Raymond LD; Pascutti PG; Caughey B; Cordeiro Y
PLoS One; 2014; 9(1):e84531. PubMed ID: 24400098
[TBL] [Abstract][Full Text] [Related]
3. Prion therapeutics: Lessons from the past.
Shim KH; Sharma N; An SSA
Prion; 2022 Dec; 16(1):265-294. PubMed ID: 36515657
[TBL] [Abstract][Full Text] [Related]
4. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.
Koster T; Singh K; Zimmermann M; Gruys E
J Vet Pharmacol Ther; 2003 Oct; 26(5):315-26. PubMed ID: 14633183
[TBL] [Abstract][Full Text] [Related]
6. In silico strategies on prion pathogenic conversion and inhibition from PrP
Pagadala NS; Syed K; Bhat R
Expert Opin Drug Discov; 2017 Mar; 12(3):241-248. PubMed ID: 28118747
[TBL] [Abstract][Full Text] [Related]
7. Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods.
Li L; Wei W; Jia WJ; Zhu Y; Zhang Y; Chen JH; Tian J; Liu H; He YX; Yao X
J Comput Aided Mol Des; 2017 Dec; 31(12):1053-1062. PubMed ID: 29159521
[TBL] [Abstract][Full Text] [Related]
8. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
Hosokawa-Muto J; Kamatari YO; Nakamura HK; Kuwata K
Antimicrob Agents Chemother; 2009 Feb; 53(2):765-71. PubMed ID: 19015328
[TBL] [Abstract][Full Text] [Related]
9. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
[TBL] [Abstract][Full Text] [Related]
10. Experimental approaches to TSE prevention via inhibition of prion formation.
Politopoulou G
Protein Pept Lett; 2004 Jun; 11(3):249-55. PubMed ID: 15182226
[TBL] [Abstract][Full Text] [Related]
11. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
12. A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.
Ferreira NC; Ascari LM; Hughson AG; Cavalheiro GR; Góes CF; Fernandes PN; Hollister JR; da Conceição RA; Silva DS; Souza AMT; Barbosa MLC; Lara FA; Martins RAP; Caughey B; Cordeiro Y
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133563
[TBL] [Abstract][Full Text] [Related]
13. Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep.
Lim K; Kim SY; Lee B; Segarra C; Kang S; Ju Y; Schmerr MJ; Coste J; Kim SY; Yokoyama T; An SS
Int J Nanomedicine; 2015; 10(Spec Iss):241-50. PubMed ID: 26425091
[TBL] [Abstract][Full Text] [Related]
14. In silico/in vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives.
Zaccagnini L; Rossetti G; Tran TH; Salzano G; Gandini A; Colini Baldeschi A; Bolognesi ML; Carloni P; Legname G
Eur J Med Chem; 2020 Jun; 196():112295. PubMed ID: 32325366
[TBL] [Abstract][Full Text] [Related]
15.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
16. Identification of compounds inhibiting prion replication and toxicity by removing PrP
Biggi S; Pancher M; Stincardini C; Luotti S; Massignan T; Dalle Vedove A; Astolfi A; Gatto P; Lolli G; Barreca ML; Bonetto V; Adami V; Biasini E
J Neurochem; 2020 Jan; 152(1):136-150. PubMed ID: 31264722
[TBL] [Abstract][Full Text] [Related]
17. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
18. Small Molecules with Anti-Prion Activity.
Mustazza C; Sbriccoli M; Minosi P; Raggi C
Curr Med Chem; 2020; 27(33):5446-5479. PubMed ID: 31560283
[TBL] [Abstract][Full Text] [Related]
19. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
[TBL] [Abstract][Full Text] [Related]
20. SPR biosensor as a tool for screening prion protein binders as potential antiprion leads.
Chen B
Methods Mol Biol; 2010; 627():147-55. PubMed ID: 20217619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
